// App-Quantinova.ai

PB2389 : Fixed Dose Rivaroxaban Can Be Prescribed in Extremes of Bodyweight, Results of a Population Pharmacokinetic Analysis

Researchers

Presenter

  • V. Speed

Principal Investigators

  • B. Green

  • L. Roberts

  • S. Woolcombe

  • J. Bartoli-Abdou

  • S. Barsam

  • R. Byrne

  • E. Gee

  • J. Czuprynska

  • A. Brown

  • S. Duffy

  • B. Vadher

  • R. Patel

  • V. Scott

  • A. Gazes

  • R. Arya

  • J. Patel

Medical Centers

  • Kings College Hospital London, Department of Haematological Medicine, London, United Kingdom

  • King's College London, Institute of Pharmaceutical Science, London, United Kingdom

  • Model Answers Pty Ltd, Brisbane, Australia

  • King's College Hospital, Department of Internal Medicine, London, United Kingdom

Locations

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Renal insufficiency

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Fixed Dose

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved